Garrett M. Brodeur: PEEL-224 will serve as a prototype for the development of future nanomedicines
Garrett M. Brodeur, Professor of Pediatrics, and Director, Cancer Predisposition Program at The Children’s Hospital of Philadelphia, reshared a post by Peel Therapeutics on LinkedIn, adding:
“It has been a longstanding goal to develop more effective, less toxic therapy for children with cancer.
It has been my honor to work with this tremendous team, including Drs. Michael Chorny and Ivan Alferiev in initial development and preclinical testing, Dr. Josh Schiffman and colleagues at PEEL Therapeutics to complete development and clear the hurtles for FDA approval, and Drs. Ted Laetsch and Jacquelyn Crane to design and carry out the phase 1/2 pediatric trial.
We are cautiously optimistic that PEEL-224 will serve as a prototype for the development of future nanomedicines that are chemically optimized to overcome drug resistance and designed to deliver more drug to the tumor and less to the patient.”
Quoting Peel Therapeutics‘s post:
“Excited for Children’s Hospital of Philadelphia (CHOP) and their patients who now have access to PEEL-224 through a new CHOP-sponsored clinical trial.
It’s been fantastic to work with CHOP colleagues to reach this pediatric milestone in PEEL-224 development, a drug originally developed at CHOP. Congrats to the whole team at CHOP, including Garrett M. Brodeur, Michael Chorny, Ivan Alferiev, Jacquelyn Crane, and Theodore Laetsch.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023